Utrecht University and Bruker Announce Collaboration to Develop Methods for Studying Protein Structures and Interactions by Mass Spectrometry

Crosslinking Mass Spectrometry (XL-MS) Now Can Leverage the PhoX Crosslinker and TIMS/PASEF Methods with the Large-Scale Use of Accurate Collision Cross Sections (CCS)

BILLERICA, Massachusetts – August 7, 2020 – Bruker Corporation (Nasdaq: BRKR) today announced a collaboration with Utrecht University to advance the study of the 3-D structures and interactions of proteins by mass spectrometry. The laboratory of Albert Heck at Utrecht University has been a leader in proteomics and the study of protein structure and interactions by mass spectrometry for over two decades. Richard Scheltema recently joined Utrecht University as group leader to focus on crosslinking mass spectrometry (XL-MS) for structural and interaction proteomics.

The collaborative work will focus on the development of TIMS (Trapped Ion Mobility Spectrometry) and PASEF (Parallel Accumulation Serial Fragmentation) methods, along with crosslinkers and XL-MS software for the timsTOF Pro 4D-Proteomics mass spectrometer, in order to take advantage of its unique large-scale, accurate CCS workflows. These have been described in the foundational paper “Benefits of Collisional Cross Section Assisted Precursor Selection (caps-PASEF) for Cross-linking Mass Spectrometry “, just published in a breakthrough paper in Molecular and Cellular Proteomics.1

Bruker plans to commercialize the results of the collaboration as integrated solutions for the study of protein structures and interactions using XL-MS. Combining the novel, enrichable PhoX crosslinker2, developed by Heck and Scheltema, with the extreme speed and sensitivity of PASEF methods on the timsTOF Pro platform, enables the discovery of more crosslinked products which yield more information about protein structures and interactions. Advanced analysis software is key, as XL-MS data is more complex and even more information-rich than typical shot-gun proteomics experiments. Scheltema is working on enabling the innovative XlinkX software to process TIMS/PASEF data and making it available to the community of timsTOF Prousers.

Albert Heck of Utrecht University

Albert Heck of Utrecht University commented: “We are delighted to work with Bruker on the further development of workflows for XL-MS that take advantage of the speed of PASEF and the unique large-scale, accurate CCS data to enhance the detection of crosslinks in XL-MS. We are excited by the initial results published in Molecular and Cellular Proteomics and look forward to advancing XL-MS even further. We are also interested in other applications of ion mobility separation and CCS on the timsTOF Pro to glycoproteomics and top-down proteomics.”

Richard Scheltema of Utrecht University

Dr. Gary Kruppa, the Vice President of Proteomics at Bruker, said: “Having personally been involved in some of the conceptual work in XL-MS in 2001 at Sandia National Laboratory, I believe the advances made by Heck’s group will make this technique more routinely available for structural biology studies using the timsTOF Pro. Our collaboration with Utrecht University will accelerate adoption of XL-MS within the broader structural and interaction proteomics community.”

Richard Scheltema of Utrecht University stated: “My group intends to push the boundaries of PASEF to enhance XL-MS workflows by making them CCS-aware. We have a significant ongoing effort in bioinformatics applied to analyzing XL-MS data using our XlinkX software.3 We are excited to work with the open data-format architecture of the timsTOF Pro in XlinkX to develop code that can use large-scale, accurate CCS values for the identification of crosslinks and to further improve false discovery rate (FDR) calculations.”

1.    Benefits of Collisional Cross Section Assisted Precursor Selection (caps-PASEF) for Cross-linking Mass Spectrometry. Steigenberger B, van den Toorn H, Bijl E, Greisch JF, Räther O, Lubeck M, Pieters RJ, Heck AJR, Scheltema RA., Mol Cell Proteomics, 2020 Jul 21:mcp.RA120.002094. doi: 10.1074/mcp.RA120.002094. Online ahead of print.

2.    PhoX: An IMAC-Enrichable Cross-Linking Reagent. Steigenberger B, Pieters RJ, Heck AJR, Scheltema RA. ACS Cent Sci. 2019 Sep 25;5(9):1514-1522.

3.    Proteome-wide profiling of protein assemblies by cross-linking mass spectrometry. Liu F, Rijkers DT, Post H, Heck AJ. Nat Methods. 2015 Dec 12(12):1179-84. doi: 10.1038/nmeth.3603

4.    Klykov, O., Steigenberger, B., Pektaş, S. et al. Efficient and robust proteome-wide approaches for cross-linking mass spectrometry. Nat Protoc 2018 Dec 13, 2964–2990. doi.org/10.1038/s41596-018-0074-x

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.

About the Heck-lab & Scheltema-lab at Utrecht University

The research groups of Albert Heck and Richard Scheltema are embedded in the Science Faculty of Utrecht University (NL). A large emphasis of the group is on the development and applications of advanced mass spectrometry-based proteomics technologies. Complementary to the proteomics efforts, the group is also well-known for its expertise in mass spectrometry based structural biology, pioneering methods in native mass spectrometry and cross-linking mass spectrometry. The group coordinates the European Proteomics Research Infrastructure (EPIC-XS, link epic-xs.eu) and heads the proteomics core in the Dutch X-Omics Initiative (www.x-omics.nl).